title: Letter from the editor.
authors.affiliation: a Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel.
authors.forename: Ronald
authors.initials: R
authors.lastname: Ellis
authors.forename: Eva M
authors.initials: EM
authors.lastname: Riedmann
mesh_terms: D001424:Bacterial Infections / Q000276:immunology / Q000517:prevention & control; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008288:Malaria / Q000276:immunology / Q000517:prevention & control; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D016896:Treatment Outcome; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014777:Virus Diseases / Q000276:immunology / Q000517:prevention & control
chemical_list: D001428:Bacterial Vaccines; D017780:Malaria Vaccines; D014765:Viral Vaccines